All In Biotech

Drug Trial Radar · NCT03103542

Study of rFVIIIFc for Immune Tolerance Induction (ITI) in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI Therapies

A Non-Controlled, Open-Label, Multicenter, Study of Immune Tolerance Induction Performed With rFVIIIFc Within a Timeframe of 60 Weeks in Severe Haemophilia A Patients With Inhibitors Who Have Failed Previous Immune Tolerance Induction Therapies

Last checked: Nov 20, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

16

Actual

Start

Aug 29, 2017

Primary completion

Sep 4, 2019

Study completion Aug 31, 2020

Sponsor

Lead sponsor
Swedish Orphan BiovitrumIndustry
Sponsor type
Industry
Collaborators
Bioverativ Therapeutics Inc.
First posted
Apr 6, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to describe the outcome of Immune Tolerance Induction (ITI) treatment performed with rFVIIIFc within a timeframe of 60 weeks in patients with haemophilia A who have failed previous attempts at tolerization.

Conditions

  • Hemophilia A

Interventions

  • Recombinant coagulation factor (rFVIIIFc)Biological

    rFVIIIFc 200 IU/kg/day during ITI Period and thereafter adjusted according to the Investigator's judgement administered intravenously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ITI SuccessTime frame: up to 60 weeks

Locations

12 sites in 7 countries. Site status is shown where the registry gives one.

  • Swedish Orphan Biovitrum Research Site

    Washington D.C., District of Columbia

  • Swedish Orphan Biovitrum Research Site

    Hamilton, Canada

  • Swedish Orphan Biovitrum Research Site

    Vancouver, Canada

  • Swedish Orphan Biovitrum Research Site

    Bonn, Germany

  • Swedish Orphan Biovitrum Research Site

    Frankfurt am Main, Germany

  • Swedish Orphan Biovitrum Research Site

    Mörfelden-Walldorf, Germany

  • Swedish Orphan Biovitrum Research site

    Dublin, Ireland

  • Swedish Orphan Biovitrum Research Site

    Ljubljana, Slovenia

  • Swedish Orphan Biovitrum Research site

    Gothenburg, Sweden

  • Swedish Orphan Biovitrum Research Site

    Birmingham, United Kingdom

  • Swedish Orphan Biovitrum Research Site

    Liverpool, United Kingdom

  • Swedish Orphan Biovitrum Research Site

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.